Fineline Cube

Follow:
14435 Articles
Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
CompanyDrug

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma

Junshi Biosciences' Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
CompanyDrug

Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment

Shandong Boan's Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
CompanyDrug

Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment

Boehringer Ingelheim's HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
CompanyDrug

Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets
CompanyDeals

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets

Tigermed Partners with Africare BioPharma to Enhance Africa's Clinical Research Capabilities
CompanyDeals

Tigermed Partners with Africare BioPharma to Enhance Africa’s Clinical Research Capabilities

Johnson & Johnson's Rybrevant Approved by China's NMPA for EGFR-Mutant NSCLC Treatment
CompanyDrug

Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors
CompanyDrug

Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors

Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline
Company

Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline

Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter
CompanyDeals

Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter

Teleflex's Rüsch EZ-Blocker Gets NMPA Approval for China Market
CompanyDrug

Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million
CompanyDeals

Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million